Effects of Intravenous and Oral Magnesium on Reducing Migraine: A Meta-analysis of Randomized Controlled Trials
Chiu HY, Yeh TH, Huang YC, Chen PY
Pain physician · 54 citations
How it was studied
- Design
- Meta-analysis (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- University or hospital
- Taipei Medical University
- Grants
- Taipei Medical University (TMU103-AE1-B11)
Based on 1 listed funder(s).
Publication
- Published
- 2016-01-14 · Pain Physician · vol. 1;19 · issue 1;1 · pp. E97–E112
- Publisher
- American Society of Interventional Pain Physicians
- Cited
- 98 citations · more than 78% of similar papers · 1.5× the field average
- References
- 47 works
- Access
- Free to read
- Research areas
- Migraine and Headache Studies · Magnesium in Health and Disease · Traumatic Brain Injury and Neurovascular Disturbances
- Keywords
- Migraine, Medicine, Randomized controlled trial, Magnesium, Meta-analysis, Anesthesia, Randomization, Internal medicine
- MeSH
- humans, magnesium, treatment outcome, administration, oral, migraine disorders, randomized controlled trials as topic, administration, intravenous
1 author
From TW
- Pin‐Yuan Chen · correspondingChang Gung University; Linkou Chang Gung Memorial Hospital
Abstract
Background
Migraine attack has been associated with magnesium deficiency. Previous studies investigating the effect of intravenous and oral magnesium on acute migraine attacks and the prevention of migraine have produced equivocal findings.
Objective
To evaluate the effects of intravenous magnesium on acute migraine attacks and oral magnesium supplements on migraine prophylaxis.
Study design
A meta-analysis of randomized controlled trials (RCTs). Electronic databases, namely EMBASE, PubMed, the Wanfang Data Chinese Database, and the China Knowledge Resource Integrated Database were searched from inception to February 24, 2015.
Methods
This review was conducted according to the guidelines of the PRISMA. Only RCTs evaluating the effects of intravenous or oral magnesium on migraine compared with a control group were included.
Results
A total of 21 studies were included. Of which, 11 studies investigated the effects of intravenous magnesium on acute migraine (948 participants) and 10 examined the effects of oral magnesium on migraine prophylaxis (789 participants). Intravenous magnesium significantly relieved acute migraine within 15 - 45 minutes, 120 minutes, and 24 hours after the initial infusion (Odd ratios [ORs] = 0.23, 0.20, and 0.25, respectively). Oral magnesium significantly alleviated the frequency and intensity of migraine (ORs = 0.20 and 0.27).
Limitations
Some of the included studies did not adopt adequate randomization methods.
Conclusions
Intravenous magnesium reduces acute migraine attacks within 15 - 45 minutes, 120 minutes, and 24 hours after the initial infusion and oral magnesium alleviates the frequency and intensity of migraine. Intravenous and oral magnesium should be adapted as parts of multimodal approach to reduce migraine.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.